Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner
With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.
AnaBios Corp. (focused on pain and cardiovascular and neurodegenerative diseases) closed a $10m Series B round, which included a $4.2m investment from Italian VC firm Principia SGR. The company will use the proceeds to expand contract research operations and advance drug programs, which incorporate its Phase X ex vivo preclinical discovery technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
